BRAIN and NERVE－神経研究の進歩76巻1号

2024年01月発行

特集 新時代の重症筋無力症と関連疾患の診療

成人重症筋無力症の診療

著者： 鵜沢顕之¹

所属機関： ¹千葉大学大学院医学研究院脳神経内科学

ページ範囲：P.13 - P.18

文献概要

重症筋無力症は神経筋接合部に存在する自己抗体が産生されることで神経筋伝導が障害され，全身の筋力低下をきたす難病である。ステロイドや免疫抑制薬での治療が中心に行われるが寛解状態は得がたい。早期速効性治療戦略により予後の改善は得られているものの，治療目標の達成率は十分とは言えず，新規分子標的薬の開発が盛んに行われている。治療法の多様化や発症年齢の高齢化などに伴い，重症筋無力症診療を取り巻く状況は大きく変化しており，本論では成人重症筋無力症の診療について概説する。

参考文献

1）Suzuki S, Masuda M, Uzawa A, Nagane Y, Konno S, et al: Japan MG registry: chronological surveys over 10 years. Clin Exp Neuroimmunol 14: 5-12, 2023

2）Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, et al: Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry 94: 467-473, 2023

3）Uzawa A, Utsugisawa K: Biological therapies for myasthenia gravis. Expert Opin Biol Ther 23: 253-260, 2023

4）日本神経学会（監修）, 重症筋無力症／ランバート・イートン筋無力症候群診療ガイドライン作成委員会（編）: 重症筋無力症／ランバート・イートン筋無力症候群診療ガイドライン2022. 南江堂, 東京, 2022

5）Grob D, Brunner N, Namba T, Pagala M: Lifetime course of myasthenia gravis. Muscle Nerve 37: 141-149, 2008

6）Masuda M, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, et al: The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve 46: 166-173, 2012

7）Ozawa Y, Uzawa A, Yasuda M, Kojima Y, Onishi Y, et al: Long-term outcomes and prognostic factors in generalized myasthenia gravis. J Neurol 268: 3781-3788, 2021

8）Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF; REGAIN study group: ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol 267: 1991-2001, 2020

9）Mendoza M, Tran C, Bril V, Katzberg HD, Barnett C: Patient-acceptable symptom states in myasthenia gravis. Neurology 95: e1617-e1628, 2020［doi: 10.1212/WNL0000000000010574］

10）Nagane Y, Suzuki S, Suzuki N, Utsugisawa K: Early aggressive treatment strategy against myasthenia gravis. Eur Neurol 65: 16-22, 2011

11）Murai H, Utsugisawa K, Nagane Y, Suzuki S, Imai T, et al: Rationale for the clinical guidelines for myasthenia gravis in Japan. Ann N Y Acad Sci 1413: 35-40, 2018

12）Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, et al; REGAIN Study Group: Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16: 976-986, 2017

13）Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, et al: Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid 1: EVIDoa2100066, 2022［doi: 10.1056/EVIDoa2100066］

14）Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, et al; RAISE Study Team: Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22: 395-406, 2023

15）Howard JF Jr, Bril V, Vu T, Karam C, Peric S, et al; ADAPT Investigator Study Group: Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20: 526-536, 2021

16）Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, et al; MG0003 study team: Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22: 383-394, 2023